This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Disclosure: This post may contain affiliate links. This means, we may receive a small commission if you choose to purchase something from a link we post (including links to amazon.com because we are a participant in the Amazon Services LLC Associates Program. Don’t worry, it won’t cost you anything. This small percentage just helps us keep the power on and the Diet Coke stocked. We appreciate your support!
Fodor is more enthusiastic about the LipoSonix technology. "I am very optimistic," he says." I love the results," he says citing as much as a 7-centimeter reduction in waist circumference seen in clinical trials conducted in Mexico. This technology, which uses high-intensity ultrasound waves, beamed about an inch under the skin to break up fatty tissue, has been studied in both pig models and in 33 people in Mexico, he says. The company has applied for FDA status to begin preclinical studies in the U.S. and expects such trials to begin in 2007.
The “AXA PPP Group” for this purpose is AXA PPP healthcare Group Limited, its holding company and all subsidiaries of its holding company including (but not limited to) AXA PPP healthcare Limited, AXA ICAS Limited, AXA ICAS Occupational Health Services Limited, Health on Line Company UK Limited and AXA PPP healthcare Administration Services Limited.